Do AutoZone Q4 Earnings Mean It Is on the Right Track?
AutoZone reported better-than-expected fiscal fourth-quarter financial results before the markets opened on Tuesday.
All Work
Chris Lange
Monday’s Biggest Winners and Losers in the S&P 500
Monday was a positive day for the U.S. broad markets with all three major averages touching a new all-time high in the session. Crude oil was flat on the day but overall Oil &…
Will Dimension Therapeutics Take the New and Bigger Buyout Offer?
Dimension Therapeutics saw one of the largest gains on the day after it came to light that the firm received an acquisition offering from Ultragenyx Pharmaceutical.
Can Earnings Get AutoZone Back on Track?
AutoZone shares have taken a beating in 2017 so far at the hands of weak earnings, industry sales trends, and the specter of Amazon.com.
Why Merrill Lynch Is Pushing Nvidia to All-Time Highs
Nvidia is now a staple in the tech industry after experiencing explosive growth in just the past couple of years, and it doesn’t look like shares will be slowing down any time soon.
Deciphera Pharma Takes Another Step Closer to IPO
Deciphera Pharmaceuticals expects to price more than 6 million shares in a range that results in an initial public offering valued up to more than $122 million.
Pluristem Wins Key FDA Approval
Shares of Pluristem Therapeutics saw a handy gain early Monday after the company said it had received a key update from the FDA.
Roku Announces Potential Pricing for IPO
Roku intends to price more than 15 million shares in a range that results in an initial public offering valued up to more than $252 million.
Why Nabriva Shares Are Doubling
Nabriva Therapeutics watched its shares more than double to kick off the week after the firm announced results from its late-stage trial in patients with community-acquired bacterial pneumonia.
Adobe, FedEx and More Earnings Coming This Week
24/7 Wall St. has put together a preview of Adobe, FedEx and a few other major companies scheduled to report their quarterly results this coming week.
5 Companies That Stand to Win Big This Hurricane Season
It’s currently estimated that the flood damage and destruction to the overall infrastructure of Houston and the surrounding areas from Hurricane Harvey can be measured in the billions. But who stands to gain the…
Nightstar Therapeutics Announces Potential Pricing for IPO
Nightstar Therapeutics intends to price more than 5 million shares in a range that results in an initial public offering valued up to more than $92 million.
What Argus Has to Say About the Equifax Hack
Equifax saw its shares continue to fall early on Friday, over a week after it came to light that the firm had been hacked.
T2 Biosystems Prices Secondary Offering
T2 Biosystems saw its shares drop handily early on Friday after the firm announced that it would be pricing its secondary offering.
Krystal Biotech Gears Up for IPO
Gene therapy company Krystal Biotech expects to price 3 million shares so that the entire offering is valued up to nearly $38 million.
Why Oracle Earnings Are So Great
Oracle Corp. (NYSE: ORCL) released its fiscal first-quarter financial results after the markets closed on Thursday. The software giant said that it had $0.62 in earnings per share (EPS) and $9.2 billion in revenue,…
Thursday’s Biggest Winners and Losers in the S&P 500
Overall Thursday was a mixed day for the U.S. broad markets. Although the S&P 500 and DJIA did hit all-time interday highs, only the Dow closed at a new high. Crude oil was again…
Why Pfizer Is Pushing the Dow to All-Time Highs
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day.
What to Expect From Oracle Earnings
Oracle is scheduled to release its fiscal first-quarter financial results after the markets close on Thursday.
First Data Prices Secondary Offering
First Data shares took a step back on Thursday after the company announced the pricing of its secondary offering.